Profectus BioSciences
Blood & Organ Banks · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
6411 Beckley St Ste 201, Baltimore, Mary...Phone Number
(443) 885-0610Website
www.profectusbiosciences.comRevenue
$24.3 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
2
2
1
About Profectus BioSciences
About Profectus Biosciences, Inc.: Profectus BioSciences, Inc. is a clinical-stage vaccine platform company developing novel vaccines for the prevention and treatment of infectious diseases and associated cancers. Profectus' vaccines are based on the company's proprietary vaccine delivery platforms to provide protection against emerging infectious diseases of public health and biodefense importance such as Ebola, Marburg, Chikungunya, Zika, the equine encephalitis viruses, and respiratory syncytial virus; and therapeutically targeting virally infected cells and cancers associated with hepatitis B virus (HBV), human papilloma virus (HPV), herpes simplex virus type 2 (HSV-2), and human immunodeficiency virus (HIV).Explore more
Profectus BioSciences Org Chart
DM
Level Two Senior Research Scientist
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Profectus BioSciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Profectus BioSciences launches new products
Check if Profectus BioSciences has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Profectus BioSciences has new funding data
Congratulate Masked Content for being promoted to Masked Content at Profectus BioSciences
Check out if Profectus BioSciences is spiking on competitors!
Profectus BioSciences, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Profectus BioSciences had a recent Job posting/layoffs
Earning: See what the market has to say on Profectus BioSciences recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Profectus BioSciences as Masked Content
Find 3 more new buyers
Compare Similar Companies to Profectus BioSciences
Compare insights from companies similar to Profectus BioSciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Profectus BioSciences is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Profectus BioSciences is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Profectus BioSciences.
Profectus BioSciences financials insights
Gather financial insights about Profectus BioSciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Private Equity
$3M
2009
Series C
$5M
2010
Grant
$4.4M
2011
Grant
$5.4M
2014
Other Financing Round
$7.3M
2015
Grant
$4.6M
Profectus BioSciences Tech Stack
A closer look at the technologies used by Profectus BioSciences
Most Recent Scoops
Lateral Move
Executive Move
John Eldridge, who previously served as Chief Scientific Officer Vacancies, has been named Chief Scientific Officer (Vacancies).
Executive Moves, Lateral Move, Personnel Moves
Funding
Profectus BioSciences recently secured $4.6 million in grant funding.
Funding
Funding
Profectus BioSciences recently secured $9.5 million in grant funding.
Funding
Funding
Funding
Profectus BioSciences News & Media
CEPI Awards Contract Worth up to $36 million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine
OSLO, Norway, BALTIMORE and GAITHERSBURG, Md., Aug. 16, 2018 (GLOBE NEWSWIRE) -- CEPI (the Coalition for Epidemic Preparedness Innovations) today announced a new collaboration with Profectus BioSciences, Inc. and Emergent BioSolutions Inc. (NYSE: EBS) under which they will receive up to USD$36 million to advance the development and manufacture of a vaccine against the Lassa virus—an estimated 100,000 to 300,000 cases of Lassa virus infection occur each year.1 ...CEPI Awards Contract Worth up to $36 million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine
OSLO, Norway, BALTIMORE and GAITHERSBURG, Md., Aug. 16, 2018 (GLOBE NEWSWIRE) -- CEPI (the Coalition for Epidemic Preparedness Innovations) today announced a new collaboration with Profectus BioSciences, Inc. and Emergent BioSolutions Inc. (NYSE: EBS) under which they will receive up to USD$36 million to advance the development and manufacture of a vaccine against the Lassa virus—an estimated 100,000 to 300,000 cases of Lassa virus infection occur each year.1 ...CEPI Awards Contract Worth up to $36 million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine
OSLO, Norway, BALTIMORE and GAITHERSBURG, Md., Aug. 16, 2018 (GLOBE NEWSWIRE) -- CEPI (the Coalition for Epidemic Preparedness Innovations) today announced a new collaboration with Profectus BioSciences, Inc. and Emergent BioSolutions Inc. (NYSE: EBS) under which they will receive up to USD$36 million to advance the development and manufacture of a vaccine against the Lassa virus—an estimated 100,000 to 300,000 cases of Lassa virus infection occur each year.1CEPI Awards $25 Million Contract to Profectus BioSciences and Emergent BioSolutions to Develop Nipah Virus Vaccine
OSLO, Norway and BALTIMORE and GAITHERSBURG, Md., May 24, 2018 (GLOBE NEWSWIRE) -- CEPI—the Coalition for Epidemic Preparedness Innovations—today announced a collaboration with Profectus BioSciences, Inc. and Emergent BioSolutions Inc. (NYSE:EBS) under which Profectus and Emergent will receive up to $25 million to advance the development and manufacture of a vaccine against the Nipah virus (NiV), a bat-borne virus that can spread to both humans and livestock. ...
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Profectus BioSciences
Sign Up For FreeTo access detailed company insights
About Profectus Biosciences, Inc.: Profectus BioSciences, Inc. is a clinical-stage vaccine platform company developing novel vaccines for the prevention and treatment of infectious diseases and associated cancers. Profectus' vaccines are based on the company's proprietary vaccine delivery platforms to provide protection against emerging infectious... Read More
